Novavax | NVAX - Pre Tax Profit


Novavax reported $17.9M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Adma Biologics USD 57.13M 4.47M Mar/2026
Agenus USD 39.21M 49.82M Mar/2026
AstraZeneca USD 4.81B 894M Jun/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Cassava Sciences USD -10.81M 33.41M Sep/2025
Geron USD -3.64M 27.5M Mar/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
MannKind USD -16.37M 4.56M Mar/2026
Merck USD -3.53B 6.95B Mar/2026
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Moderna USD -1.33B 535M Mar/2026
Novartis USD 3.84B 1.33B Mar/2026
Novavax USD 17.9M 220.94M Dec/2025
Pfizer USD -653M 5.84B Jun/2026
Sanofi EUR 837M 1.17B Jun/2026
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
TG Therapeutics USD 10.23M 10.13M Jun/2026